文献速递基础与转化研究临床试验与 GCP

晚期胃肠道肿瘤中循环肿瘤DNA分析指导的靶向治疗

Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors.
PubMed 文献 · Nat Med · 2024-09-16

GOZILA研究是一项全国性前瞻性观察性ctDNA分析研究,更新分析纳入4037例晚期实体瘤患者,靶向治疗匹配率为24%。基于ctDNA匹配靶向治疗的患者总生存显著优于未匹配治疗者(HR 0.54)。生物标志物克隆性和校正血浆拷贝数可预测疗效,支持ctDNA指导治疗的更广泛应用。

要点

  • ctDNA分析指导靶向治疗匹配率为24%。
  • 匹配靶向治疗者总生存优于未匹配者(HR 0.54)。
  • 生物标志物克隆性和校正血浆拷贝数可预测疗效。

核心结论

  • ctDNA分析指导的靶向治疗可改善晚期实体瘤患者生存,支持更广泛采用ctDNA指导治疗。

研究设计与样本

  • GOZILA研究为全国性前瞻性观察性ctDNA分析研究,更新分析纳入4037例晚期实体瘤患者。

主要发现

  • 基于ctDNA分析的靶向治疗匹配率为24%。
  • 接受匹配靶向治疗的患者总生存显著优于接受未匹配治疗者(HR 0.54)。
  • 生物标志物克隆性和校正血浆拷贝数被确定为疗效预测因素。

临床怎么用

  • 作者主张更广泛采用ctDNA指导的治疗,以推进精准肿瘤学并改善晚期实体瘤生存结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although comprehensive genomic profiling has become standard in oncology for advanced solid tumors, the full potential of circulating tumor DNA (ctDNA)-based profiling in capturing tumor heterogeneity and guiding therapy selection remains underexploited, marked by a scarcity of evidence on its clinical impact and the assessment of intratumoral heterogeneity. The GOZILA study, a nationwide, prospective observational ctDNA profiling study, previously demonstrated higher clinical trial enrollment rates using liquid biopsy compared with tissue screening. This updated analysis of 4,037 patients further delineates the clinical utility of ctDNA profiling in advanced solid tumors, showcasing a significant enhancement in patient outcomes with a 24% match rate for targeted therapy. Patients treated with matched targeted therapy based on ctDNA profiling demonstrated significantly improved overall survival compared with those receiving unmatched therapy (hazard ratio, 0.54). Notably, biomarker clonality and adjusted plasma copy number were identified as predictors of therapeutic efficacy, reinforcing the value of ctDNA in reflecting tumor heterogeneity for precise treatment decisions. These new insights into the relationship between ctDNA characteristics and treatment outcomes advance our understanding beyond the initial enrollment benefits. Our findings advocate for the broader adoption of ctDNA-guided treatment, signifying an advancement in precision oncology and improving survival outcomes in advanced solid tumors.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Nakamura Y, Ozaki H, Ueno M, et al. Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors. Nat Med. 2024. PMID: 39284955. doi:10.1038/s41591-024-03244-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。